Characteristics of Adolescents and Youth with Recent-onset Type 2 Diabetes: the TODAY Cohort at Baseline
Overview
Authors
Affiliations
Context: The Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) cohort represents the largest and best-characterized national sample of American youth with recent-onset type 2 diabetes.
Objective: The objective of the study was to describe the baseline characteristics of participants in the TODAY randomized clinical trial.
Design: Participants were recruited over 4 yr at 15 clinical centers in the United States (n = 704) and enrolled, randomized, treated, and followed up 2-6 yr.
Setting: The study was conducted at pediatric diabetes care clinics and practices.
Participants: Eligible participants were aged 10-17 yr inclusive, diagnosed with type 2 diabetes for less than 2 yr and had a body mass index at the 85th percentile or greater.
Interventions: After baseline data collection, participants were randomized to one of the following groups: 1) metformin alone, 2) metformin plus rosiglitazone, or 3) metformin plus a lifestyle program of weight management.
Main Outcome Measures: Baseline data presented include demographics, clinical/medical history, biochemical measurements, and clinical and biochemical abnormalities.
Results: At baseline the cohort included the following: 64.9% were female; mean age was 14.0 yr; mean diabetes duration was 7.8 months; mean body mass index Z-score was 2.15; 89.4% had a family history of diabetes; 41.1% were Hispanic, 31.5% were non-Hispanic black; 38.8% were living with both biological parents; 41.5% had a household annual income of less than $25,000; 26.3% had a highest education level of parent/guardian less than a high school degree; 26.3% had a blood pressure at the 90th percentile or greater; 13.6% had a blood pressure at the 95th percentile or greater; 13.0% had microalbuminuria; 79.8% had a low high-density lipoprotein level; and 10.2% had high triglycerides.
Conclusions: The TODAY cohort is predominantly from racial/ethnic minority groups, with low socioeconomic status and a family history of diabetes. Clinical and biochemical abnormalities and comorbidities are prevalent within 2 yr of diagnosis. These findings contribute greatly to our understanding of American youth with type 2 diabetes.
Rodacki M, Zajdenverg L, da Silva Junior W, Giacaglia L, Negrato C, Cobas R Diabetol Metab Syndr. 2025; 17(1):78.
PMID: 40038723 PMC: 11881304. DOI: 10.1186/s13098-024-01572-w.
Nadeau K, Arslanian S, Bacha F, Caprio S, Chao L, Farrell R Diabetologia. 2024; 68(3):676-687.
PMID: 39706874 DOI: 10.1007/s00125-024-06327-w.
ISPAD Clinical Practice Consensus Guidelines 2024: Type 2 Diabetes in Children and Adolescents.
Shah A, Barrientos-Perez M, Chang N, Fu J, Hannon T, Kelsey M Horm Res Paediatr. 2024; 97(6):555-583.
PMID: 39675348 PMC: 11854986. DOI: 10.1159/000543033.
14. Children and Adolescents: Standards of Care in Diabetes-2025.
Diabetes Care. 2024; 48(Supplement_1):S283-S305.
PMID: 39651980 PMC: 11635046. DOI: 10.2337/dc25-S014.
Moran M, Thompson T, Jimenez V, Gutierrez-Colina A, Clark N, Sanchez N Int J Behav Med. 2024; .
PMID: 39477857 DOI: 10.1007/s12529-024-10331-0.